Letter | Published:

p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence

Nature Cell Biology volume 11, pages 11351142 (2009) | Download Citation

Abstract

The finite proliferative potential of normal human cells leads to replicative cellular senescence, which is a critical barrier to tumour progression in vivo1,2,3. We show that the human p53 isoforms Δ133p53 and p53β4 function in an endogenous regulatory mechanism for p53-mediated replicative senescence. Induced p53β and diminished Δ133p53 were associated with replicative senescence, but not oncogene-induced senescence, in normal human fibroblasts. The replicatively senescent fibroblasts also expressed increased levels of miR-34a, a p53-induced microRNA5,6,7,8,9, the antisense inhibition of which delayed the onset of replicative senescence. The siRNA (short interfering RNA)-mediated knockdown of endogenous Δ133p53 induced cellular senescence, which was attributed to the regulation of p21WAF1 and other p53 transcriptional target genes. In overexpression experiments, whereas p53β cooperated with full-length p53 to accelerate cellular senescence, Δ133p53 repressed miR-34a expression and extended the cellular replicative lifespan, providing a functional connection of this microRNA to the p53 isoform-mediated regulation of senescence. The senescence-associated signature of p53 isoform expression (that is, elevated p53β and reduced Δ133p53) was observed in vivo in colon adenomas with senescent phenotypes10,11. The increased Δ133p53 and decreased p53β isoform expression found in colon carcinoma may signal an escape from the senescence barrier during the progression from adenoma to carcinoma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).

  2. 2.

    , & Cellular senescence in cancer and aging. Cell 130, 223–233 (2007).

  3. 3.

    , & An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008).

  4. 4.

    et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122–2137 (2005).

  5. 5.

    et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298–1307 (2007).

  6. 6.

    et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745–752 (2007).

  7. 7.

    et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130–1134 (2007).

  8. 8.

    et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26, 731–743 (2007).

  9. 9.

    , , & Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA 104, 15472–15477 (2007).

  10. 10.

    et al. p16INK4a expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119, 929–942 (2000).

  11. 11.

    et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).

  12. 12.

    , , & The telomere hypothesis of cellular aging. Exp. Gerontol. 27, 375–382 (1992).

  13. 13.

    et al. p53 isoform Δ113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 23, 278–290 (2009).

  14. 14.

    et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20, 2803–2808 (2000).

  15. 15.

    et al. Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res. 67, 11677–11686 (2007).

  16. 16.

    , & TRF2 protects human telomeres from end-to-end fusions. Cell 92, 401–413 (1998).

  17. 17.

    , & Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277, 831–834 (1997).

  18. 18.

    , , , & Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a. Mol. Cell 14, 501–513 (2004).

  19. 19.

    , & miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 105, 13421–13426 (2008).

  20. 20.

    et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 27, 5204–5213 (2008).

  21. 21.

    et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 68, 3193–3203 (2008).

  22. 22.

    , & Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biol. 8, 877–884 (2006).

  23. 23.

    , , , & Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363–374 (2008).

  24. 24.

    , , & Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci. 118, 485–496 (2005).

  25. 25.

    et al. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc. Natl. Acad. Sci. USA 104, 8334–8339 (2007).

  26. 26.

    et al. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27, 1562–1571 (2008).

  27. 27.

    , , & Amyloid-β precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene 26, 7302–7312 (2007).

  28. 28.

    & p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 14, 3–9 (2007).

  29. 29.

    , , , & Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937–948 (1992).

  30. 30.

    et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866–868 (1990).

  31. 31.

    et al. Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol. Biomarkers Prev. 15, 573–577 (2006).

  32. 32.

    et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).

  33. 33.

    et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299–1307 (2004).

  34. 34.

    et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).

  35. 35.

    , , , & Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).

  36. 36.

    , & An amino-terminally truncated p53 protein expressed in a human choriocarcinoma cell line, CC1. Hum. Mol. Genet. 4, 313–314 (1995).

  37. 37.

    et al. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J. 22, 1210–1222 (2003).

  38. 38.

    et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273, 11995–11998 (1998).

  39. 39.

    , , , & Metabolism of 1, 2-dimethylhydrazine by cultured human colon. Carcinogenesis 1, 375–380 (1980).

  40. 40.

    et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425–436 (2008).

Download references

Acknowledgements

We thank M. Serrano, M. Tainsky, M. Oshimura, G. Hannon, T. de Lange and J. Khan for cells and reagents, X. Wang for helpful discussions, E. Spillare for continuous support and E. Michalova for technical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute (NCI). B.V. was supported by the grants from the Grant Agency of the Czech Republic (GACR; number 301/08/1468) and the Internal Grant Agency of Health of Czech Republic (IGA MZ CR; number NS/9812-4). J.C.B. was supported by Breast Cancer Campaign, Cancer-Research UK (CRUK) and the Institut National de la Sante et de la Recherche Medicale (Inserm). D.L. is a Gibb fellow of CRUK. H. J. participated in the NIH Summer Internship Program.

Author information

Affiliations

  1. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892-4258, USA.

    • Kaori Fujita
    • , Abdul M. Mondal
    • , Izumi Horikawa
    • , Giang H. Nguyen
    • , Kensuke Kumamoto
    • , Jane J. Sohn
    • , Elise D. Bowman
    • , Ewy A. Mathe
    • , Aaron J. Schetter
    • , Sharon R. Pine
    • , Helen Ji
    •  & Curtis C. Harris
  2. Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, 1 Cloister Court, Building 60, Bethesda, MD 20814-1460, USA.

    • Giang H. Nguyen
  3. Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653 Brno, Czech Republic.

    • Borivoj Vojtesek
  4. University of Dundee, Ninewells Hospital, Department of Surgery and Molecular Oncology, Inserm-European Associated Laboratory, Dundee, DD1 9SY, UK.

    • Jean-Christophe Bourdon
    •  & David P. Lane
  5. Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673, Singapore.

    • David P. Lane

Authors

  1. Search for Kaori Fujita in:

  2. Search for Abdul M. Mondal in:

  3. Search for Izumi Horikawa in:

  4. Search for Giang H. Nguyen in:

  5. Search for Kensuke Kumamoto in:

  6. Search for Jane J. Sohn in:

  7. Search for Elise D. Bowman in:

  8. Search for Ewy A. Mathe in:

  9. Search for Aaron J. Schetter in:

  10. Search for Sharon R. Pine in:

  11. Search for Helen Ji in:

  12. Search for Borivoj Vojtesek in:

  13. Search for Jean-Christophe Bourdon in:

  14. Search for David P. Lane in:

  15. Search for Curtis C. Harris in:

Contributions

K.F., A.M.M., I.H., G.H.N., K.K., J.J.S., E.D.B., A.J.S., S.R.P. and H.J. performed experiments. E.A.M. provided expertise on statistical data analysis. B.V., J.-C.B. and D.P.L. provided essential reagents and suggestions. K.F., I.H. and C.C.H. coordinated the study and wrote the manuscript. C.C.H. was responsible for the overall project. All authors discussed the results and commented on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Curtis C. Harris.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncb1928

Further reading